Abstract
The immune system avoids oncogenesis and slows down tumor progression through a mechanism called immunosurveillance. Nevertheless, some malignant cells manage to escape from immune control and form clinically detectable tumors. Tetraploidy, which consists in the intrinsically unstable duplication of the genome, is considered as a (pre)-cancerous event that can result in aneuploidy and contribute to oncogenesis. We previously described the fact that tetraploid cells can be eliminated by the immune system. Here, we investigate the role of different innate and acquired immune effectors by inoculating hyperploid cancer cells into wild type or mice bearing different immunodeficient genotypes (Cd1d-/-, FcRn-/-, Flt3l-/-, Foxn1nu/nu, MyD88-/-, Nlrp3-/-, Ighmtm1Cgn, Rag2-/-), followed by the monitoring of tumor incidence, growth and final ploidy status. Our results suggest that multiple different immune effectors including B, NK, NKT and T cells, as well as innate immune responses involving the interleukine-1 receptor and the Toll-like receptor systems participate to the immunoselection against hyperploid cells. Hence, optimal anticancer immunosurveillance likely involves the contribution of multiple arms of the immune system.
References
Mar 6, 1992·Cell·Y ShinkaiA M Stall
Apr 4, 1991·Nature·D KitamuraK Rajewsky
Jan 1, 1970·Progress in Experimental Tumor Research·F M Burnet
Feb 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S IkeharaR A Good
Aug 1, 1994·Immunopharmacology and Immunotoxicology·W Budzynski, C Radzikowski
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Mar 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Derry C RoopenianClark L Anderson
Nov 25, 2003·Immunology·Mark A ExleySteven P Balk
Aug 27, 2005·Carcinogenesis·Andrew J OlaharskiDavid A Eastmond
Oct 14, 2005·Nature·Takeshi FujiwaraDavid Pellman
Dec 7, 2005·Journal of Cellular Physiology·Hao G Nguyen, Katya Ravid
May 6, 2006·The EMBO Journal·Maria CastedoGuido Kroemer
Nov 21, 2007·Nature·Catherine M KoebelRobert D Schreiber
Mar 7, 2008·Expert Opinion on Investigational Drugs·George D Kalliolias, Stamatis-Nick C Liossis
Jul 29, 2008·Immunity·Baidong HouAnthony L DeFranco
Apr 1, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Hao G NguyenKatya Ravid
Jun 11, 2009·Carcinogenesis·Daiko WakitaTakashi Nishimura
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Apr 30, 2011·Nature Reviews. Molecular Cell Biology·Ilio VitaleGuido Kroemer
Aug 2, 2011·Annual Review of Cell and Developmental Biology·Teresa Davoli, Titia de Lange
May 5, 2012·PloS One·Sheri L BonarGabriel Mbalaviele
May 10, 2012·PLoS Genetics·Judit PampalonaLaura Tusell
Jun 16, 2012·Cancer Cell·Teresa Davoli, Titia de Lange
Aug 17, 2012·Cell Cycle·Maria CastedoGuido Kroemer
Aug 25, 2012·Cell Cycle·Joshua M Nicholson, Daniela Cimini
Aug 29, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·O J Finn
Sep 29, 2012·Science·Laura SenovillaGuido Kroemer
Jan 18, 2013·Cell Cycle·Alice BoilèveGuido Kroemer
Jul 31, 2013·Immunity·Laurence ZitvogelGuido Kroemer
Jul 31, 2013·Trends in Immunology·Laura SenovillaGuido Kroemer
Oct 31, 2015·Oncotarget·Norma BloyLaura Senovilla
Apr 9, 2016·Oncoimmunology·Andrea Acebes-HuertaSegundo Gonzalez
Sep 25, 2017·Trends in Cell Biology·Alejandro López-SotoGuido Kroemer
Oct 14, 2017·Immunological Reviews·Norma BloyGuido Kroemer
Dec 26, 2017·Cell·Alexander D BarrowMarco Colonna